Thomas Hofstaetter
Keine laufenden Positionen mehr
Profil
Thomas Hofstaetter served as President, Chief Executive Officer & Director at VaxInnate Corp.
and as an Independent Director at Geron Corp.
and Valerio Therapeutics SA. He was also a Director at Merial, Inc. and Senior Vice President-Corporate Development at Aventis, Inc. and Wyeth, Inc. Additionally, he served as a Non-Executive Director at Bionor Pharma ASA and as a Trustee at New Jersey Symphony Orchestra.
Hofstaetter holds graduate and doctorate degrees from Eberhard Karls Universität Tübingen.
Ehemalige bekannte Positionen von Thomas Hofstaetter
| Unternehmen | Position | Ende |
|---|---|---|
| VALERIO THERAPEUTICS | Director/Board Member | 23.11.2021 |
Bionor Pharma ASA
 Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Director/Board Member | 01.05.2016 |
| GERON CORPORATION | Director/Board Member | 18.05.2015 |
VaxInnate Corp.
 VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Chief Executive Officer | 02.04.2012 |
Wyeth, Inc. /Biopharmaceutical Manufacturing Operations/
 Wyeth, Inc. /Biopharmaceutical Manufacturing Operations/ BiotechnologyHealth Technology Part of Johnson & Johnson, Wyeth, Inc. /Biopharmaceutical Manufacturing Operations/ is a private company that manufactures biopharmaceutical products. The company is based in New York, NY. Wyeth, Inc. /Biopharmaceutical Manufacturing Operations was acquired by Centocor, Inc. from Wyeth LLC on April 06, 2004. | Corporate Officer/Principal | 01.10.2009 |
Ausbildung von Thomas Hofstaetter
| Eberhard Karls Universität Tübingen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| Private Unternehmen | 7 |
|---|---|
| Aventis, Inc. | |
Behringwerke AG
 Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The private company is based in Marburg, Germany. | Health Technology |
Wyeth, Inc. /Biopharmaceutical Manufacturing Operations/
Wyeth, Inc. /Biopharmaceutical Manufacturing Operations/ BiotechnologyHealth Technology Part of Johnson & Johnson, Wyeth, Inc. /Biopharmaceutical Manufacturing Operations/ is a private company that manufactures biopharmaceutical products. The company is based in New York, NY. Wyeth, Inc. /Biopharmaceutical Manufacturing Operations was acquired by Centocor, Inc. from Wyeth LLC on April 06, 2004. | Health Technology |
Merial, Inc.
 Merial, Inc. Pharmaceuticals: MajorHealth Technology Merial, Inc. develops pharmaceutical products and vaccines for pets and wildlife. It provides healthcare products and food for dogs, cats, cattle, horse, and poultry producers. The company was founded in August 1997 and is headquartered in Duluth, GA. | Health Technology |
VaxInnate Corp.
VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Health Technology |
| New Jersey Symphony Orchestra | |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Health Technology |
